Singapore- In Singapore, it is estimated that 16 people die from CVDs (heart diseases and stroke) per day, and CVDs accounted for 29.5% of all deaths in 2016. This means that nearly 1 out of 3 deaths in Singapore, is due to heart diseases or stroke.

On NHC’s plans to strengthen its cardiovascular treatment capabilities, Dr Hsu Li Fern, Co-CEO and Consultant Cardiologist, NHC, said, “With the support of Luye Medical Group, NHC aims to set up more clinics in the major private hospitals in Singapore to enhance accessibility for patients, as well as expand our one-stop integrated treatment and diagnosis centre. Being part of a bigger medical group will also allow us to leverage Luye Medical Group’s capabilities and further enhance our suite of cardiac healthcare solutions, bringing greater value to our patients.”

Underpinning NHC’s solid reputation has been an exemplary record of medical excellence – this includes several notable achievements such as being the first in Singapore and Asia to do a left ventricular assist device (LVAD) procedure for a patient as destination therapy in 2011; being the first to do Coronary Artery Disease Risk Assessment (CADRA) testing in collaboration with National University of Singapore in 2011; and subsequently offering genetic resistance for Plavix resistance in 2012.

Further afield, in the mid-term, Luye Medical Group intends to expand NHC’s cardiology practice into China.

“We will tap the Company’s strong local network in China to bring NHC’s cardiology practice to the country. Our foray into the key Chinese cities will be aligned with the upcoming hospitals under the Luye Medical Group’s umbrella of healthcare assets in China. Our overarching aim is to deliver world-class clinical outcomes and value-based healthcare to our patients,” added Mr Wang.